Elevated circulating resistin concentrations (top vs lowest third) were associated with an increased risk of incident heart failure over 6 years (HR 4.01; 95% CI 1.52-10.57; P=0.004 for trend).
Cohort (n=2,739)
Are circulating concentrations of resistin and adiponectin associated with incident heart failure in participants of the Framingham Offspring Study?
Elevated circulating concentrations of resistin, but not adiponectin, are independently associated with an increased risk of incident heart failure.
Hazard Ratio: 4.01 (95% CI 1.52–10.57)
p-value: p=0.004 for trend
Objective We tested the association of the adipokines resistin and adiponectin with incident heart failure. Background Abnormal concentrations of adipokines may partially explain the association between obesity and heart failure. Methods We related circulating adipokine concentrations to the incidence of heart failure in 2,739 participants in the Framingham Offspring Study. Results During six years of follow-up, 58 participants developed new-onset heart failure. In proportional hazards models (adjusting for age, sex, blood pressure, antihypertensive treatment, diabetes, smoking, total/HDL cholesterol ratio, prevalent coronary heart disease, valvular heart disease, left ventricular hypertrophy and estimated glomerular filtration rate) using the lowest third of the resistin distribution as the referent, the hazard ratios (HRs) for heart failure in the middle and top thirds were 2.89 (95% confidence interval 1.05–7.92) and 4.01 (1.52–10.57), respectively (P=0.004 for trend). Additional adjustment for body mass index, insulin resistance (measured with the homeostasis model), C-reactive protein and B-type natriuretic peptide did not substantively weaken this association (multivariable HRs 2.62 and 3.74, P=0.007). In the maximally-adjusted model, each standard deviation increment in resistin (7.45 ng/ml) was associated with a 26% increase in heart failure risk (95% CI -1–60%). Concentrations of adiponectin were not associated with heart failure (multivariable HRs 0.87 and 0.97, P=0.9). Conclusions Elevated circulating concentrations of resistin were associated with incident heart failure, even after accounting for prevalent coronary heart disease, obesity, and for measures of insulin resistance and inflammation. The findings suggest a role for resistin in human disease and a novel pathway to heart failure.
“This is one of the strongest predictors of new-onset heart failure we've been able to find, and it holds up even when you control for other biomarkers and risk factors including high blood pressure and diabetes.”
Frankel et al. (2008) conducted a cohort in Incident heart failure (n=2,739). Elevated circulating resistin concentrations vs. Lowest third of the resistin distribution was evaluated on Incident heart failure (HR 4.01, 95% CI 1.52-10.57, p=0.004 for trend). Elevated circulating resistin concentrations (top vs lowest third) were associated with an increased risk of incident heart failure over 6 years (HR 4.01; 95% CI 1.52-10.57; P=0.004 for trend).